# A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

> **NCT06520488** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 118 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HRS-4642

## Key facts

- **NCT ID:** NCT06520488
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-09
- **Primary completion:** 2027-03
- **Final completion:** 2027-07
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06520488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06520488, "A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06520488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*